Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study.
Document Type
Article
Publication Date
7-5-2024
Publication Title
Prostate cancer and prostatic diseases
Abstract
BACKGROUND/OBJECTIVES: Based on the SPARTAN and TITAN studies, apalutamide is approved for patients with nonmetastatic castration-resistant and metastatic castration-sensitive prostate cancer. Skin rash was a common adverse reaction across indications. We hypothesized that earlier identification and intervention could improve rash outcomes.
SUBJECTS/METHODS: A prespecified rash management guide outlining recommended skin care practices was provided to all patients enrolled in Apa-RP (NCT04523207). Rash-related safety data from Apa-RP were compared descriptively with data from SPARTAN and TITAN.
RESULTS: Patients in Apa-RP experienced improved rash-related outcomes vs those in SPARTAN and TITAN.
CONCLUSIONS: Increased vigilance and proactive management may reduce the incidence, severity, and duration of rash during apalutamide treatment.
Volume
Online ahead of print
Recommended Citation
Shore N, Hafron J, Saltzstein D, Bhaumik A, Aggarwal P, Phillips J et al. Impact of a rash management guide in patients receiving apalutamide for high-risk localized prostate cancer in the Apa-RP study. Prostate Cancer Prostatic Dis. 2024 Jul 5. doi: 10.1038/s41391-024-00858-4. Epub ahead of print. PMID: 38969791.
DOI
10.1038/s41391-024-00858-4
ISSN
1476-5608
PubMed ID
38969791